Pixium Vision SA (0QVB.L)
| Previous close | 0.1940 |
| Open | 0.1913 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.1913 - 0.1913 |
| 52-week range | 0.1913 - 0.1913 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 37,427 |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2310 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Pixium Vision announces participation in investor conferences and events in October 2022
Pixium Vision announces participation in investor conferences and events in October 2022 Paris, France, October 4, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following investor events in October 2022: Biotech Agora, October 12, Paris Lloyd D
- Globe Newswire
Pixium Vision to host open house event for investors on October 13th 2022 from 5 pm
Pixium Vision to host open house eventfor investors on October 13th 2022 from 5 pm Registration needed – Limited availability Paris, France, September 21, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today it will host an open house event for investors on Thursday, October 13th, 2022. The event,
- Globe Newswire
Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022
Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022 The target number of 38 patients have been enrolled at clinical sites in France, Germany, the UK, the Netherlands, and ItalyWaiting list for additional patients initiated to replace potential pre-implantation drop-outs and ineligibilityImplantations due to be completed by the end of 2022; PRIMAvera read-out expected around the end of 2023 Paris, Fra
